To understand the therapeutic limitations of RHAMM-R3 peptides, Snauwaert and co-workers showed that for AML patients, RHAMM expression on normal hematopoietic cells were similar to that of leukemic stem cells and that expression was cell cycle dependent. The gene discussed is HMMR; the disease is acute myeloid leukemia.